We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Testing Needed to Identify Neurologic Disorder in Men

By HospiMedica staff writers
Posted on 12 Feb 2004
Researchers have discovered a new, progressive neurologic disorder in men over 50, which can be diagnosed with a standard DNA blood test. More...
Their discovery was reported in the January 28, 2004, issue of the Journal of the American Medical Association (JAMA).

The disorder results in tremors, balance problems, and dementia that become increasingly severe with age. Many of the men are currently being mistakenly diagnosed with Parkinson's disease, senile dementia, or Alzheimer's disease. The disorder is known as fragile X-associated tremor/ataxia syndrome, or FXTAS, and it is caused by a small mutation in the same gene that causes fragile X syndrome, a common cause of inherited mental retardation. Screening for the gene mutation in men who have tremor and balance problems is important, especially when accompanied by other signs such as rigidity in movement, short-term memory loss, and dementia.

Research studies are now underway to determine which medications are better suited to alleviate the disorder, and whether therapies such as surgery to disable nerve tracks may actually exacerbate balance problems. When the researchers looked at 192 individuals from families with fragile X, they found 17% in their 50s had FXTAS but the percentage increased to 38% of men in their 60s, to 47% of men in their 70s, and 75% of men in their 80s.

"The disorder appears later in life in men who are generally healthy throughout childhood and early-to-mid adulthood and have normal-to-above-average intelligence, yet is caused by a defect in a gene known to cause mental retardation usually diagnosed in early childhood,” explained Dr. Randi Hagerman, medical director of the University of California, Davis, M.I.N.D. Institute (USA).

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.